8-K: Cross Country Healthcare Sets 2026 Annual Meeting, Revises Deadlines
Annual Meeting Announcement
Cross Country Healthcare, Inc. announced its 2026 Annual Meeting will be held on May 11, 2026, and revised deadlines for stockholder proposals and director nominations due to the advanced meeting date.
Summary
- The 2026 Annual Meeting of Stockholders for Cross Country Healthcare, Inc. is scheduled for May 11, 2026.
- The meeting will be held virtually, with the specific time and website address to be detailed in the upcoming proxy statement.
- The proxy statement for the 2026 Annual Meeting is expected to be made available to stockholders on or about March 31, 2026.
- Due to the meeting date being advanced by more than 30 days compared to the anniversary of the 2025 Annual Meeting, revised deadlines for stockholder proposals and nominations have been established.
- Stockholder proposals intended for inclusion in the Company's proxy statement under Rule 14a-8 must be received by March 11, 2026.
- Stockholder proposals for business or director nominations, as per the Company's Amended and Restated Bylaws, must be delivered by February 10, 2026.
- Stockholders planning to solicit proxies in support of director nominees under the universal proxy rules (Rule 14a-19) must provide notice by March 12, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, administrative update. It provides necessary information for shareholders but does not contain news that would typically impact the company's financial performance or strategic direction.
Future Outlook
The company has set the date for its 2026 Annual Meeting and provided deadlines for shareholder participation, indicating a standard progression of corporate governance activities for the upcoming year.
Management Comments
- William J. Burns, Executive Vice President & Chief Financial Officer, signed the report on behalf of Cross Country Healthcare, Inc.
Industry Context
StockSavvy.ai notes that the announcement of an annual meeting date and associated deadlines is a routine corporate governance event for publicly traded companies, ensuring compliance with SEC regulations and facilitating shareholder engagement.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Annual Meeting Date | The 2026 Annual Meeting of Stockholders has been set for May 11, 2026, which is more than 30 days earlier than the anniversary of the 2025 meeting. | 2026-05-11 | Requires shareholders to adhere to revised, earlier deadlines for proposals and nominations. |
| Shareholder Proposal Deadlines | Revised deadlines for stockholder proposals under Rule 14a-8 (March 11, 2026), Bylaws (February 10, 2026), and universal proxy rules (March 12, 2026) have been established. | 2026-01-29 | Shareholders must submit proposals and nominations earlier than in previous years due to the advanced meeting date. |
Stakeholder Impact
- Shareholders: Must note the advanced meeting date and revised, earlier deadlines for submitting proposals and director nominations.
Next Steps
- The Company will make its proxy statement for the 2026 Annual Meeting available to stockholders on or about March 31, 2026.
- The time and website address for the virtual-only 2026 Annual Meeting will be set forth in the proxy statement.
Key Dates
| Date | Description |
|---|---|
| 2026-01-29 | Date of this 8-K report. |
| 2026-02-10 | Deadline for stockholder proposals for business or director nominations under the Company's Bylaws. |
| 2026-03-11 | Deadline for stockholder proposals to be eligible for inclusion in the Company's proxy statement pursuant to Rule 14a-8. |
| 2026-03-12 | Deadline for stockholders to provide notice under universal proxy rules (Rule 14a-19) for soliciting director nominees. |
| 2026-03-31 | Approximate date the Company's proxy statement for the 2026 Annual Meeting will be made available to stockholders. |
| 2026-05-11 | Date of the 2026 Annual Meeting of Stockholders. |
Keywords
Cross Country Healthcare, CCRN, Annual Meeting, Stockholder Meeting, Proxy Statement, Director Nominations, Shareholder Proposals, Corporate Governance, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.